This review discusses the evidence in support of the use of Semaglutide for the treatment of type 2 diabetes mellitus; its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Dr Ted Wu, a senior specialist endocrinologist and Director of the Diabetes Centre at The Royal Prince Alfred Hospital in Sydney.
Please login below to download this issue (PDF)